AtriCure to Announce Third Quarter 2013 Financial Results

  AtriCure to Announce Third Quarter 2013 Financial Results

Business Wire

WEST CHESTER, Ohio -- October 7, 2013

AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions partner
providing innovative products, professional education and support for clinical
science to reduce the economic and social burden of atrial fibrillation, will
release its financial results for the third quarter of 2013 on Tuesday,
October 29, 2013.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday,
October 29, 2013 to discuss its third quarter 2013 financial results. A live
webcast of the conference call will be available online from the investor
relations page of AtriCure’s corporate website at www.atricure.com.

Pre-registration is available and recommended for this call at the following
URL:

https://www.theconferencingservice.com/prereg/key.process?key=PYKGA4LEN

You may also access this call through an operator by calling (888) 713-4211
for domestic callers and (617) 213-4864 for international callers at least 15
minutes prior to the call start time using reservation code 83850169.

The webcast will be available on AtriCure’s website and a telephonic replay of
the call will also be available through November 29, 2013. The replay dial-in
numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for
international callers. The reservation code is 29085641.

About AtriCure, Inc.

AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing
innovative products, professional education and support for clinical science
to reduce the economic and social burden of atrial fibrillation. AtriCure's
Synergy Ablation System is the first and only device approved by the Food and
Drug Administration (FDA) for the surgical treatment of Persistent and
Longstanding Persistent forms of Afib in patients undergoing certain open
heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left
Atrial Appendage (LAA) occlusion device is the most widely implanted device
for LAA management worldwide.Afib affects more than two million people
worldwide and is estimated to cost more than $6.5 billion annually in
healthcare expenses. The number affected by Afib is expected to grow to 12
million by 2050.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
or
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.